The current landscape of predictive and prognostic biomarkers for immune checkpoint blockade in ovarian cancer
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The current landscape of predictive and prognostic biomarkers for immune checkpoint blockade in ovarian cancer
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 13, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-10-27
DOI
10.3389/fimmu.2022.1045957
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Overexpression of CAPG Is Associated with Poor Prognosis and Immunosuppressive Cell Infiltration in Ovarian Cancer
- (2022) Senwei Jiang et al. DISEASE MARKERS
- CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer
- (2022) Stefanie Seitz et al. BRITISH JOURNAL OF CANCER
- Novel insights into the interaction between N6-methyladenosine modification and circular RNA
- (2022) Tao Xu et al. Molecular Therapy-Nucleic Acids
- Artificial intelligence-derived gut microbiome as a predictive biomarker for therapeutic response to immunotherapy in lung cancer: protocol for a multicentre, prospective, observational study
- (2022) Fumihiro Shoji et al. BMJ Open
- Identification of NAD+ Metabolism-Derived Gene Signatures in Ovarian Cancer Prognosis and Immunotherapy
- (2022) Liang Lin et al. Frontiers in Genetics
- Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors
- (2022) Rachel E Sanborn et al. Journal for ImmunoTherapy of Cancer
- Gene signature of m6A-related targets to predict prognosis and immunotherapy response in ovarian cancer
- (2022) Wei Tan et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer
- (2021) Moran Yang et al. Journal for ImmunoTherapy of Cancer
- Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics
- (2021) Julianne D. Twomey et al. AAPS Journal
- Evaluation of Serum Biomarker CEA and Ca-125 as Immunotherapy Response Predictors in Metastatic Non-small Cell Lung Cancer
- (2021) MAX R. CLEVERS et al. ANTICANCER RESEARCH
- Tertiary Lymphoid Structures as a Predictive Biomarker of Response to Cancer Immunotherapies
- (2021) Marta Trüb et al. Frontiers in Immunology
- Identification of biomarkers complementary to homologous recombination deficiency for improving the clinical outcome of ovarian serous cystadenocarcinoma
- (2021) Zhiwen Shi et al. Clinical and Translational Medicine
- ARID1A mutation/ARID1A loss is associated with a high immunogenic profile in clear cell ovarian cancer
- (2021) Yuka Kuroda et al. GYNECOLOGIC ONCOLOGY
- Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study
- (2021) Eric Pujade-Lauraine et al. LANCET ONCOLOGY
- Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer
- (2021) Christine S. Walsh et al. PLoS One
- Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates
- (2021) John B Liao et al. Journal for ImmunoTherapy of Cancer
- The Liquid Biopsy for Lung Cancer: State of the Art, Limitations and Future Developments
- (2021) Daniel Di Capua et al. Cancers
- Landscape of Immune Microenvironment in Epithelial Ovarian Cancer and Establishing Risk Model by Machine Learning
- (2021) Shi-yi Liu et al. Journal of Oncology
- Identification of a Gene Set Correlated With Immune Status in Ovarian Cancer by Transcriptome-Wide Data Mining
- (2021) Lili Fan et al. Frontiers in Molecular Biosciences
- Biomarkers of immunotherapy response in breast cancer beyond PD-L1
- (2021) Nuria Chic et al. BREAST CANCER RESEARCH AND TREATMENT
- Improved prediction of immune checkpoint blockade efficacy across multiple cancer types
- (2021) Diego Chowell et al. NATURE BIOTECHNOLOGY
- Comprehensive Analyses Identify APOBEC3A as a Genomic Instability-Associated Immune Prognostic Biomarker in Ovarian Cancer
- (2021) Fangfang Xu et al. Frontiers in Immunology
- Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers
- (2021) Jinzhu Mao et al. Journal for ImmunoTherapy of Cancer
- Immune Cell Infiltration Landscape of Ovarian Cancer to Identify Prognosis and Immunotherapy-Related Genes to Aid Immunotherapy
- (2021) Xiushen Li et al. Frontiers in Cell and Developmental Biology
- High TGF-β signature predicts immunotherapy resistance in gynecologic cancer patients treated with immune checkpoint inhibition
- (2021) Ying Ni et al. npj Precision Oncology
- Pembrolizumab monotherapy in Japanese patients with advanced ovarian cancer: Subgroup analysis from the KEYNOTE‐100
- (2020) Shin Nishio et al. CANCER SCIENCE
- A phase Ib study of the anti-CD47 antibody magrolimab with the PD-L1 inhibitor avelumab (A) in solid tumor (ST) and ovarian cancer (OC) patients.
- (2020) Nehal J. Lakhani et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase 2 study
- (2020) Erika J Lampert et al. CLINICAL CANCER RESEARCH
- Final results from the KEYNOTE-100 trial of pembrolizumab in patients with advanced recurrent ovarian cancer.
- (2020) Ursula A. Matulonis et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study
- (2020) Dmitriy Zamarin et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
- (2020) Anniina Färkkilä et al. Nature Communications
- Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial
- (2020) Elizabeth K. Lee et al. GYNECOLOGIC ONCOLOGY
- Utility of serum CA-125 monitoring in patients with ovarian cancer undergoing immune checkpoint inhibitor therapy
- (2020) Julia L. Boland et al. GYNECOLOGIC ONCOLOGY
- Expression of STAT1 is positively correlated with PD-L1 in human ovarian cancer
- (2020) Fangran Liu et al. CANCER BIOLOGY & THERAPY
- Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer
- (2020) Emese Zsiros et al. JAMA Oncology
- Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer
- (2019) Mary L. Disis et al. JAMA Oncology
- Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study
- (2019) U A Matulonis et al. ANNALS OF ONCOLOGY
- Are Integrins Still Practicable Targets for Anti-Cancer Therapy?
- (2019) Alday-Parejo et al. Cancers
- Gut Microbiome: A Promising Biomarker for Immunotherapy in Colorectal Cancer
- (2019) Sally Temraz et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer
- (2019) Joyce F. Liu et al. JAMA Oncology
- PD-L1 expression in tumour-infiltrating lymphocytes is a poor prognostic factor for primary acral melanoma patients
- (2018) Min Ren et al. HISTOPATHOLOGY
- Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
- (2018) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
- (2018) Jun Gong et al. Journal for ImmunoTherapy of Cancer
- Anti-CD27 agonist antibody varlilumab (varli) with nivolumab (nivo) for colorectal (CRC) and ovarian (OVA) cancer: Phase (Ph) 1/2 clinical trial results.
- (2018) Rachel E. Sanborn et al. JOURNAL OF CLINICAL ONCOLOGY
- Current advancement on diagnosis of ovarian cancer using biosensing of CA 125 biomarker: Analytical approaches
- (2018) Nasrin Razmi et al. TRAC-TRENDS IN ANALYTICAL CHEMISTRY
- Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study
- (2017) Jung-Min Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- Monitoring immune-checkpoint blockade: response evaluation and biomarker development
- (2017) Mizuki Nishino et al. Nature Reviews Clinical Oncology
- Predictive biomarkers for checkpoint inhibitor-based immunotherapy
- (2016) Geoffrey T Gibney et al. LANCET ONCOLOGY
- Tumor infiltrating lymphocytes in ovarian cancer
- (2015) Phillip P Santoiemma et al. CANCER BIOLOGY & THERAPY
- CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients
- (2013) P. A. Ott et al. CLINICAL CANCER RESEARCH
- CXCL14 is a natural inhibitor of the CXCL12-CXCR4 signaling axis
- (2013) Kosuke Tanegashima et al. FEBS LETTERS
- Integrins and metastasis
- (2013) Kirat Kumar Ganguly et al. Cell Adhesion & Migration
- Heterotrimeric G-proteins: a short history
- (2006) Graeme Milligan et al. BRITISH JOURNAL OF PHARMACOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now